相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study
Mijin Kim et al.
THYROID (2023)
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives
Olga Karapanou et al.
ENDOCRINE-RELATED CANCER (2022)
CAR-NK cell in cancer immunotherapy; A promising frontier
Faroogh Marofi et al.
CANCER SCIENCE (2021)
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
Reza Elahi et al.
STEM CELL REVIEWS AND REPORTS (2021)
DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro
Yao Huang et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Natural killer cells in cancer biology and therapy
Song-Yang Wu et al.
MOLECULAR CANCER (2020)
Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib
Naoki Fukuda et al.
IN VIVO (2020)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients
Jonghwa Ahn et al.
THYROID (2019)
The role of cytokines in the regulation of NK cells in the tumor environment
Gordana M. Konjevic et al.
CYTOKINE (2019)
Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer
Viswanath Gunda et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
Takayuki Kimura et al.
CANCER SCIENCE (2018)
Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
Kevin G. Pinz et al.
ONCOTARGET (2017)
Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: a systematic review and meta-analysis
Wen Li et al.
ONCOTARGET (2017)
Natural Killer Cell (NK-92MI)-Based Therapy for Pulmonary Metastasis of Anaplastic Thyroid Cancer in a Nude Mouse Model
Liya Zhu et al.
FRONTIERS IN IMMUNOLOGY (2017)
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
Masahiro Matsuki et al.
CANCER SCIENCE (2017)
Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Rasmus Laursen et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysis
Tomohiro F. Nishijima et al.
CANCER TREATMENT REVIEWS (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
Kiyoshi Okamoto et al.
CANCER LETTERS (2013)
From tumor cell metabolism to tumor immune escape
Martin Villalba et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma
Qiang-Bo Zhang et al.
PLOS ONE (2013)
Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies
Enrique Grande et al.
JOURNAL OF THYROID RESEARCH (2012)
分享论文
